An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Sponsor: Virogin Biotech Canada Ltd
This PHASE2 trial investigates Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma and is currently actively recruiting participants. Virogin Biotech Canada Ltd leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Apr 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
May 2022 — Sep 2023 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Virogin Biotech Canada Ltd
For direct contact, visit the study record on ClinicalTrials.gov .